Praktické lékárenství – 1E/2021

www.praktickelekarenstvi.cz e13 AKTUÁLNÍ FARMAKOTERAPIE Erektilní dysfunkce a možnosti její terapie pohledem lékárníka PRAKTICKÉ LÉKÁRENSTVÍ dysfunction: new treat‑ment approach using once daily tadalafi l. Urologe A 2009; 48(11): 1320–1329. 16. Ismail EA, El‑Sakka AI. Innovative trends and perspectives for erectile dysfunction tre‑ atment: A systematic review. Arab J Urol. 2016;14(2): 84–93. 17. Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: a systema‑ tic review and meta‑analysis. BJU Int. 2003. 92(4): 441–446. 18. Rezaee ME, Gross MS. Are We Overstating the Risk of PriapismWith Oral Phosphodies‑ terase Type 5 Inhibitors?. J Sex Med. 2020;17(8): 1579–1582. 19. Šrámková T. Terapie erektilní dysfunkce dle Guidelines Evropské urologické asociace. Kardiol Rev Int Med 2014; 16(4): 288–293. 20. Derouet H, Weirauch A, Bewermeier H. Prostaglandin E1 (PGE1) in diagnosis and long­ ‑term therapy of erectile dysfunction. Urologe A. 1996; 35(1): 62–67. 21. Lee S, Lee J, Choi YW. Design and evaluation of prostaglandin E1 (PGE1) intraurethral liquid formulation employing self‑microemulsifying drug delivery system (SMEDDS) for erectile dysfunction treatment. Biol Pharm Bull. 2008. 31(4): 668–672. 22. Zámečník L. Novák J. Nový typ léčby poruch erekce na trhu v ČR – aplikace alprosta‑ dilu ve formě krému. Urol. praxi 2016; 17(5): 217–222. 23. Ritchie R, Sullivan M. Endothelins & erectile dysfunction. Pharmacolog. Res. 2011; 63: 496–501. 24. Khan MA, Calvert RC, Sullivan ME, et al. Normal and pathological erectile function: the potential clinical role of endothelin-1 antagonists. Curr Drug Targets. 2000; 1(3): 247–260. 25. Borrelli F, Colalto C, Delfino DV, et al. Herbal Dietary Supplements for Erectile Dysfunc‑ tion: A Systematic Review and Meta‑Analysis. Drugs. 2018, 78(6): 643–673. 26. Shamloul R. Natural Aphrodisiacs. J. Sex. Med. 2010; 7: 39–49. 27. Jackson G, Boon N, Eardely I, et al. Eectile dysfunction and coronory artery disease pre‑ diction: evidence – based Guyance and consensus. Int J Clin Pract. 2010; 64(7): 848–857. 28. De Busc R, Drory R, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of the Princeton Consensus panel. Am J Cardiol. 2000; 86: 175–181. 29. Phé V, Roupret M. Erectile dysfunction and diabetes. A review of the current evidence­ ‑based medicine and a synthesis of the main available therapies. Diabetes Metab. 2012; 38: 1–13. 30. Morales AM, Hatzichristou D, Lladós JR, et al. Community Pharmacy Detection of Erec‑ tile Dysfunction in Men with Risk Factors or Who Seek Treatment or Advice but Lack a Va‑ lid Prescription. The Journal of Sexual Medicine. 2013, 10(9): 2303–2311. 31. Taylor DG., Giuliano F, Hackett G, et al. The pharmacist’s role in improving the treatment of erectile dysfunction and its underlying causes. Research in Social and Administrative Pharmacy. 2019; 15(5): 591–599 32. Oakley N, Moore KTH. Vacuum devices in erectile dysfunction: indications and effica‑ cy. BJU International. 1998; 82(5): 673–681. 33. Odborné poradenství v lékárnách. [online]. Česká lékárnická komora [cit. 2020-10-28]. Dostupné z: https://www.sukl.cz/modules/medication/search.php.